{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-029119","form_type":"8-K","ticker":"ACHV","cik":"0000949858","company_name":"ACHIEVE LIFE SCIENCES, INC.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.746553+00:00","generated_at":"2026-06-24T01:16:56.568823+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Achieve Life Sciences Q2 net loss $10.5M; Phase 3 success and $2.5M NIH grant","bullets":["Q2 2022 net loss of $10.5M; operating expenses $10.1M; cash & restricted cash $29.4M as of June 30.","Phase 3 ORCA-2 trial in 810 smokers: 6–8x increased odds of smoking abstinence vs placebo (statistically significant).","Awarded $2.5M NIH grant for Phase 2 ORCA-V1 trial evaluating cytisinicline in e-cigarette users; trial initiated.","ORCA-3, the final NDA-enabling smoking cessation trial, continues enrolment."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-029119","json":"https://secwatch.observer/filing/0001564590-22-029119.json","markdown":"https://secwatch.observer/filing/0001564590-22-029119.md","text":"https://secwatch.observer/filing/0001564590-22-029119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/949858/000156459022029119/0001564590-22-029119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/949858/000156459022029119/achv-8k_20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:16:56.568823+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}